CVSI — CV Sciences, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1510964 ·
Last close
$0.01
Market Cap
$2.82M
52W High
$0.10
52W Low
$0.01
ADV30
757,030
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,985,000 | 1,450,000 | -301,000 | -775,000 | 6,521,000 | 266,000 | 4,950,000 |
| Mar 2026 | 3,195,000 | 1,562,000 | -318,000 | -643,000 | 6,722,000 | 309,000 | 5,224,000 |
| Dec 2025 | 3,307,000 | 1,671,000 | -75,000 | -206,000 | 6,962,000 | 278,000 | 5,494,000 |
| Sep 2025 | 3,256,000 | 1,579,000 | -275,000 | -382,000 | 6,995,000 | 381,000 | 5,456,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-225,000
Investing CF
$-72,000
Financing CF
$-211,000
CapEx
$-72,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-88,582,000
Inventory
$3,902,000
Receivables
$391,000
ST Investments
—
EBIT TTM
$-799,000
Pretax Income TTM
$-1,490,000
Interest Exp TTM
$366,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,743,000
EBITDA
$-872,000
Free Cash Flow
$70,125
Enterprise Value
$4,780,929
Total Cash
$266,000
Total Debt
$1,253,000
Shares Out
225,829,128
Trailing EPS
$-0.02
Book Value
$0.01
ROE
-118.9%
ROA
-8.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,789,000 | -470,000 | -958,000 | 6,962,000 | 5,494,000 | 1,468,000 | -407,000 |
| Dec 2024 | 15,705,000 | -2,190,000 | -2,394,000 | 7,927,000 | 6,132,000 | 1,795,000 | -861,000 |
| Dec 2023 | 16,004,000 | 3,360,000 | 3,102,000 | 9,200,000 | 6,297,000 | 2,903,000 | 2,253,000 |
| Dec 2022 | 16,205,000 | -6,847,000 | -8,214,000 | 12,736,000 | 13,513,000 | -777,000 | -1,885,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$27,025,000
NetIncome TTM
$-5,997,000
OpCashFlow TTM
$0
Assets (Latest)
$12,736,000
Forward EPS
$-0.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ISCO | International Stem Cell CORP | $2.80M | $0.35 | — |
| SPRC | SciSparc Ltd. | $2.85M | $4.91 | — |
| SILO | Silo Pharma, Inc. | $2.89M | $1.65 | — |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $2.73M | $1.15 | — |
| VCNX | VACCINEX, INC. | $2.68M | $1.00 | — |
News headlines (Yahoo Finance, 1h cache)
CV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory Framework
2026-09-08 21:00 · Yahoo
CV Sciences Inc (CVSI) (Q2 2026) Earnings Call Highlights: Strategic Pivot to PlusHealth Amid ...
2026-08-17 19:01 · Yahoo
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
2026-08-13 20:00 · Yahoo
CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids
2026-08-12 02:30 · Yahoo
CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026
2026-08-11 00:00 · Yahoo
CV Sciences Expands +PlusHLTH(TM) Portfolio with Personalized Wellness Solutions for Healthy Aging
2026-06-26 00:00 · Yahoo
CV Sciences Inc (CVSI) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
2026-05-15 05:03 · Yahoo
CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026
2026-05-12 22:00 · Yahoo
CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results
2026-05-14 20:00 · Yahoo
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
2026-03-26 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.